Citius Pharmaceuticals announced it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research (CBER) of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. Read more...
Erba Mannheim announced the development and imminent launch of its ErbaLisa® COVID-19 ELISA kits for detection of IgG and IgM antibodies to SARS-CoV-2. Read more...
https://www.americanpharmaceuticalreview.com/1315-News/563668-ERBA-Mannheim-Launches-CE-Marked-COVID-19-Antibody-Kits/?catid=6262
Regeneron Pharmaceuticals and Sanofi announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with "severe" or "critical" respiratory illness caused by COVID-19. Read more...